KNSA Kiniksa Pharmaceuticals, Ltd.
Healthcare$52.86-0.71%ClosedMarket Cap: $3.97B
As of 2026-05-26
Valuation
P/E (TTM)
59.21
PEG
0.25
P/B
6.73
P/S
5.31
EV/EBITDA
37.64
DCF Value
$-698.90
FCF Yield
4.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
54.6%
Operating Margin
12.4%
Net Margin
9.7%
ROE
13.3%
ROA
8.9%
ROIC
9.6%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $214.3M | 55.0% | $29.3M | $22.6M | $— | — |
| Q4 null | $202.1M | 54.9% | $19.8M | $14.2M | $— | — |
| FY null | $677.6M | 54.6% | $77.2M | $59.0M | $— | — |
| Q3 null | $180.9M | 53.8% | $24.0M | $18.4M | $— | — |
| Q2 null | $156.8M | 54.7% | $20.2M | $17.8M | $— | — |
| Q1 null | $137.8M | 55.3% | $13.3M | $8.5M | $— | — |
| Q4 null | $122.5M | 46.0% | $-19.3M | $-8.9M | $— | — |
| FY null | $423.2M | 85.6% | $-45.6M | $-43.2M | $— | — |
| Q3 null | $112.2M | 56.0% | $-9.7M | $-12.7M | $— | — |
| Q2 null | $108.6M | 60.9% | $-117.0K | $-3.9M | $— | — |
| Q1 null | $79.9M | 60.5% | $-16.5M | $-17.7M | $— | — |
| Q4 2023 | $83.4M | 67.9% | $81.0K | $25.2M | $0.35 | — |